A Northeastern researcher in the Department of Pharmaceutical Sciences and the New England Inflammation and Tissue Protection Institute (NEITPI) says his lab has employed a novel gene editing technology that might make personalized treatments for cancer available “off the shelf” against solid tumors.
The platform is called base editing, says Stephen Hatfield, assistant professor at Northeastern’s Bouvé College of Health Sciences.
He says it allows multiple gene edits of cancer-fighting immune cells called CAR T cells without causing substantial DNA damage.
